Luxembourg-based Vesalius Biocapital Partners has closed its third life science fund, raising €120 million for later-stage European companies. The fundraising includes a commitment of €30 million from the European Investment Fund and new and existing investors from Europe, the Americas and the Middle East and North Africa.
